Rockfish Bio

Executive Summary

Rockfish Bio, a spin-off from BOKU and Medical University of Vienna, is pioneering senolytic therapies to selectively eliminate senescent cells, which accumulate with age and drive chronic diseases. Their platform exploits a unique metabolic vulnerability in these cells, sparing healthy cells. This approach has broad potential in age-related disorders, including fibrosis, osteoarthritis, and neurodegeneration. Currently in preclinical development, Rockfish has identified lead candidates and is advancing toward IND-enabling studies. The company's novel mechanism and strong academic foundation position it as a promising player in the burgeoning senolytics field. With aging populations and increasing interest in targeting senescence, Rockfish Bio could address significant unmet needs. Upcoming milestones include lead candidate finalization and initiation of toxicology studies, which will be critical for entering clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization and Candidate Selection80% success
• H1 2027Initiation of IND-Enabling Studies70% success
• Q2 2027Preclinical Data Presentation at Major Conference60% success